OXIS International Announces Successful Direct Mail Test for Ergoplex, an Antioxidant Dietary Supplement

- Excellent Response Rates Ranging From 1.6% to 2.2% Indicate Strong Consumer
Acceptance -

BEVERLY HILLS, Calif.--(Business Wire)--
Regulatory News:

OXIS INTERNATIONAL, INC. (Pink Sheets: OXIS, Paris: OXI) announced today that
Ergoplex, its commercial anti-inflammatory product using its patented compound,
Ergothioneine, a powerful antioxidant, has shown very good acceptance in a
recent direct mail test. Response rates ranged from 1.6% to 2.2%; levels
indicative of broad consumer acceptance.

Tony Cataldo, Chairman and CEO of Oxis, stated, "The results of the recent
direct mail test are extremely exciting and we believe this data supports our
contention that Ergoplex will be a successful product in the fight against
oxidative stress and inflammation. These tests are the first steps towards a
full launch of Ergoplex as our first commercial product. We expect to announce
additional products in our pipeline as we continue to develop our portfolio."

Contact the Company at: 310-860-5184 for additional information about OXIS, or
visit our web site: www.oxis.com.

Forward-Looking Statement

This press release contains forward-looking statements that involve numerous
risks and uncertainties. Actual results, performance or achievements could
differ materially from those anticipated in such forward-looking statements as a
result of certain factors, including those set forth in the Company`s filings
with the Securities and Exchange Commission.

About OXIS International, Inc.

OXIS International, Inc. develops technologies and products to research,
diagnose, treat and prevent diseases of oxidative stress/inflammation associated
with damage from free radical and reactive oxygen species (ROS). The company
holds the rights to several therapeutic classes of compounds in the area of
oxidative stress, and has focused commercialization programs that include SOD
(superoxide dismutase), MPO (myeloperoxidase), GPx (glutathione peroxidase), as
well as a highly potent antioxidant, Ergothioneine, that may be sold
over-the-counter (OTC) as a dietary supplement.

Oxis International, Inc.
Anthony Cataldo, 310-860-5184
Chief Executive Officer
or
Wolfe Axelrod Weinberger Associates, LLC
Stephen D. Axelrod, CFA / Adam Lowensteiner
212-370-4500

Copyright Business Wire 2009